Exonics Using CRISPR To Develop One-Time Treatment for Duchenne

 
• By Brenda Sandburg

Newly formed biotech company hopes to avoid patent melee and use gene editing technology to develop therapy for up to 80% of boys with DMD; trial outcomes to drive terms of future licensing deals.

Abstract render of earth inside a glowing DNA strand ( earth uv map from http://visibleearth.nasa.gov )

More from Legal & IP

More from Pink Sheet